Biohaven is advancing the development of Yale University-licensed MoDE platform technology

  • Biohaven is advancing the development of its extracellular target degrader platform technology (MoDEs™) for therapies in a variety of diseases including neuroscience, immunology and oncology

  • Through continuous collaboration with Yale University in the laboratory of Prof David Mirror and Biohaven Labs, Biohaven has continued to innovate in this breakthrough technology with new patent applications covering additional targets and capabilities

  • Licensed from Yale University In 2021, the MoDE platform is based on patent applications filed by jale in 2018 and 2019

NEW HAVEN, Conn., October 25, 2022 /PRNewswire/ — Biohaven Ltd. (NYSE: BHVN; “Biohaven”) today announced advances in the development of its licensed MoDE extracellular target degrader platform technology Yale University for various disease indications including but not limited to neurological disorders, cancer, infectious and autoimmune diseases.



In 2021, Biohaven entered into a worldwide, exclusive license agreement to develop and commercialize the MoDE platform based on groundbreaking research conducted in Professor’s laboratory David Mirror at Yale University. As part of the license agreement, Biohaven acquired the exclusive, worldwide rights to Yales intellectual property related to its MoDE technology, which relates to the elimination of disease-causing proteins and other biomolecules by targeting them for lysosomal degradation using multifunctional molecules.

Professor Spiegel commented: “Targeted protein degradation (TPD) has emerged as a promising and exciting therapeutic strategy, however, the majority of existing TPD technologies rely on the ubiquitin-proteasome system targeting intracellular proteins developed in MoDEs , a class of modular, bifunctional synthetic molecules capable of mediating the degradation of extracellular proteins by the asialoglycoprotein receptor (ASGPR).MoDE molecules mediate the formation of a ternary complex between a target protein and the ASGPR, the is said to be expressed primarily on hepatocytes, and the target protein is then endocytosed and degraded by lysosomal proteases. The MoDE platform differs from existing approaches such as Proteolysis TargetingChimeras (PROTAC) in that it does not rely on ubiquitin ligases and targets a wide range of targets, which are to be dismantled.”

Through the novel approach, Professor Spiegel demonstrated the modularity of MoDE technology by synthesizing bifunctional molecules that induce degradation of both antibodies and pro-inflammatory cytokine proteins. When first published, the data obtained from Spiegel Lab provided the first experimental evidence that non-proteinogenic, synthetic molecules could be used for both the TPD of extracellular proteins in vitro and in vivo.

The MoDE platform discovered at Yale University is reported in a peer-reviewed publication entitled Bifunctional Small Molecules that Mediate the Degradation of Extracellular Proteins (natural chemical biology 2021, 17, 947-953) and in various Yale University Patent applications, including those published as WO 2019/199621 and WO 2019/199634, both of which are based on provisional applications filed in 2018. Subsequent to jale Patent applications have referred to other such multifunctional molecules for extracellular protein degradation as “ASGPR targeting chimeras” (ATACs) (see e.g. or “lysosome-targeting chimeras” (LyTACs) (see e.g. Both jale and Biohaven continue to expand the platform’s underlying intellectual property portfolio with a number of new global filings disclosing and claiming various aspects of the multifunctional degraders and methods of their use. Since signing the license agreement with jale in 2021, jale has filed more than eight other patent applications for this technology.

About Biohaven.
Biohaven is a global, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing life-changing therapies for people with debilitating neurological and neuropsychiatric disorders, including rare diseases. Biohaven is advancing a pipeline of best-in-class therapies for diseases with few or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neural hyperexcitability; Glutamate modulation in obsessive compulsive disorder and spinocerebellar ataxia and myostatin inhibition in neuromuscular disease. Biohaven’s portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain and recruitment of CD-38 antibodies, bispecific molecules for multiple myeloma. For more information about Biohaven, visit

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Use of certain words including “continue”, “plan”, “will”, “believe”, “may”, “expect”. ‘, ‘anticipate’ and similar expressions are intended to identify forward-looking statements. Investors are cautioned that forward-looking statements, including statements regarding future development, timing and the potential for market approval and commercialization of development candidates are not guarantees of future performance or results and involve significant risks and uncertainties. Actual results, developments and events could differ materially from those projected in the forward-looking statements due to a number of factors, including: Biohaven’s ability to complete the offering of its common stock on the proposed terms or at all; Biohaven’s expectations regarding the use of proceeds from the offering of its common shares; the anticipated timing, initiation and results of Biohaven’s planned and ongoing clinical studies; the timing of proposed interactions and submissions to the FDA; the timing and outcome of anticipated regulatory filings; Compliance with applicable US regulatory requirements; the potential commercialization of Biohaven’s product candidates; the potential of Biohaven’s product candidates to be first-in-class or first-in-class therapies; and the efficacy and safety of Biohaven’s product candidates. Additional important factors to consider in connection with forward-looking statements are described in Biohaven’s filings with the Securities and Exchange Commission, including in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. The forward-looking statements are made as of the date of this new press release and Biohaven undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

MoDEs is a trademark of Biohaven Therapeutics Ltd.

Biohaven contact:
Jennifer Porcelli
Vice President, Investor Relations
[email protected]

Mike Beyer
Sam Brown Inc.
[email protected]



To download multimedia, view the original content: .html

SOURCE Biohaven Ltd.


Leave a Reply

Your email address will not be published. Required fields are marked *